Tumor Treating Fields May Improve Glioblastoma Outcomes

Share this content:
TTFs can be self-administered at home by patients; this novel radiation treatment is non-ionizing and delivers electrical fields directly to the brain.
TTFs can be self-administered at home by patients; this novel radiation treatment is non-ionizing and delivers electrical fields directly to the brain.

Tumor treating fields (TTFs) are safe and efficacious when used with temozolomide for glioblastoma treatment, according to a late-breaking abstract presented at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting.1

Glioblastoma carries a dismal prognosis of slightly over a year, and new therapies are badly needed. TTFs can be self-administered at home by patients; this novel radiation treatment is non-ionizing and delivers electrical fields directly to the brain.

For this randomized phase 3 trial (ClinicalTrials.gov Identifier: NCT00916409), researchers recruited 695 patients with newly diagnosed glioblastoma; patients received standard temozolomide or TTFs plus temozolomide. Progression-free survival (PFS) and overall survival (OS) were the primary endpoints; the secondary endpoint was quality of life.

With a hazard ratio of 0.63, PFS and OS were superior in the experimental group. Toxicity was similar between the 2 groups, though patients in the TTF group had worse skin toxicity.

The authors noted that, compared with the control arm, more patients in the experimental arm “reported stable or improved scores on global health status, pain, physical functioning, and leg weakness…while the area under the curve for improvement or stability over time was not significantly different between groups.”

Patients in the experimental arm also had longer deterioration-free survival.

The authors concluded that TTFs are a safe and effective novel treatment for patients with glioblastoma, which can both extend survival and improve quality of life.

Reference

  1. Stupp R, Taphoorn M, Driven L, et al. Tumor treating fields (TTFields) — a novel cancer treatment modality: translating preclinical evidence and engineering into a survival benefit with delayed decline in quality of life. Presented at: 2017 ASTRO Meeting; San Diego, CA: September 24-27, 2017. Abstract LBA-6.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters